These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP/p21/c-Myc Signaling. Zhang HT; Gui T; Sang Y; Yang J; Li YH; Liang GH; Li T; He QY; Zha ZG J Cell Biochem; 2017 Aug; 118(8):2182-2192. PubMed ID: 28059436 [TBL] [Abstract][Full Text] [Related]
3. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Ott CJ; Kopp N; Bird L; Paranal RM; Qi J; Bowman T; Rodig SJ; Kung AL; Bradner JE; Weinstock DM Blood; 2012 Oct; 120(14):2843-52. PubMed ID: 22904298 [TBL] [Abstract][Full Text] [Related]
4. Pharmacological Targeting of BET Bromodomains Inhibits Lens Fibrosis via Downregulation of MYC Expression. Wang X; Wang B; Zhao N; Wang C; Huang M; Chen B; Chen J; Sun Y; Xiong L; Huang S; Liu Y Invest Ophthalmol Vis Sci; 2019 Nov; 60(14):4748-4758. PubMed ID: 31731295 [TBL] [Abstract][Full Text] [Related]
6. JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways. Liu X; Wu H; Huang P; Zhang F J Oral Pathol Med; 2019 Jan; 48(1):43-51. PubMed ID: 30269363 [TBL] [Abstract][Full Text] [Related]
7. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells. Zanellato I; Colangelo D; Osella D Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341 [TBL] [Abstract][Full Text] [Related]
8. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma. Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906 [TBL] [Abstract][Full Text] [Related]
10. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615 [TBL] [Abstract][Full Text] [Related]
11. The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition. Yao W; Yue P; Khuri FR; Sun SY Oncotarget; 2015 Oct; 6(33):34669-79. PubMed ID: 26415225 [TBL] [Abstract][Full Text] [Related]
12. BET protein inhibitor JQ1 attenuates Myc-amplified MCC tumor growth in vivo. Shao Q; Kannan A; Lin Z; Stack BC; Suen JY; Gao L Cancer Res; 2014 Dec; 74(23):7090-102. PubMed ID: 25277525 [TBL] [Abstract][Full Text] [Related]
13. BET bromodomain inhibitor JQ1 decreases CD30 and CCR4 expression and proliferation of cutaneous T-cell lymphoma cell lines. Kamijo H; Sugaya M; Takahashi N; Oka T; Miyagaki T; Asano Y; Sato S Arch Dermatol Res; 2017 Aug; 309(6):491-497. PubMed ID: 28593508 [TBL] [Abstract][Full Text] [Related]
14. Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer. Enomoto K; Zhu X; Park S; Zhao L; Zhu YJ; Willingham MC; Qi J; Copland JA; Meltzer P; Cheng SY J Clin Endocrinol Metab; 2017 Jul; 102(7):2268-2280. PubMed ID: 28368473 [TBL] [Abstract][Full Text] [Related]
15. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. Bagratuni T; Mavrianou N; Gavalas NG; Tzannis K; Arapinis C; Liontos M; Christodoulou MI; Thomakos N; Haidopoulos D; Rodolakis A; Kastritis E; Scorilas A; Dimopoulos MA; Bamias A Eur J Cancer; 2020 Feb; 126():125-135. PubMed ID: 31927213 [TBL] [Abstract][Full Text] [Related]
16. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma. Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342 [TBL] [Abstract][Full Text] [Related]
17. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice. Tan Y; Sementino E; Pei J; Kadariya Y; Ito TK; Testa JR Cancer Biol Ther; 2015; 16(4):580-8. PubMed ID: 25793663 [TBL] [Abstract][Full Text] [Related]
18. The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer. Pang Y; Bai G; Zhao J; Wei X; Li R; Li J; Hu S; Peng L; Liu P; Mao H J Transl Med; 2022 Jul; 20(1):336. PubMed ID: 35902869 [TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines. Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological targeting of BET proteins attenuates radiation-induced lung fibrosis. Wang J; Zhou F; Li Z; Mei H; Wang Y; Ma H; Shi L; Huang A; Zhang T; Lin Z; Wu G Sci Rep; 2018 Jan; 8(1):998. PubMed ID: 29343723 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]